Press Releases

Here is an up-to-date collection of any information given to the press. It’s a big collection, so try not to look at it all in one sitting.

Press Releases

Date Title and Summary Additional Formats
Toggle Summary ZIOPHARM Oncology Announces Pricing of $50 Million Follow-On Offering of Common Stock
BOSTON, May 12, 2017 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on new immunotherapies, today announced that it has priced an underwritten follow-on offering of 9,708,738 shares of its common stock at an offering price of $5.15 per share to a
View HTML
Toggle Summary ZIOPHARM Oncology Announces FDA Acceptance of IND for CD33-Specific CAR-T Cell Therapy Targeting Relapsed/Refractory Acute Myeloid Leukemia
Phase 1 Study Expected to Initiate in Third Quarter 2017
View HTML
Toggle Summary ZIOPHARM Oncology Reports First Quarter 2017 Financial Results and Provides Update on Recent Activities
— Advancing Plans to Initiate Pivotal Study  for Ad-RTS-hIL-12 + Veledimex for Treatment of Recurrent Brain Cancer — - Company to Host Conference Call Today at 4:30 p.m. ET - BOSTON, May 01, 2017 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on new
View HTML
Toggle Summary ZIOPHARM Oncology to Host First-Quarter 2017 Financial Results and Corporate Update Conference Call on May 1, 2017 at 4:30 p.m. ET
BOSTON, April 24, 2017 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on new immunotherapies, today announced that it will host a conference call and webcast slide presentation on Monday, May 1, 2017 at 4:30 p.m.
View HTML
Toggle Summary ZIOPHARM Oncology to Present Updated Clinical Results of Gene Therapy Candidate Ad-RTS-hIL-12 + Veledimex in Recurrent Glioblastoma at the 2017 ASCO Annual Meeting
BOSTON, April 20, 2017 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on new immunotherapies, today announced that it will present updated results from its Phase 1, multicenter, dose-escalation study of Ad-RTS-hIL-12 + orally administered veledimex in
View HTML
Toggle Summary Intrexon, ZIOPHARM and Merck KGaA, Darmstadt, Germany Advancing Next-Generation Non-Viral CAR-T Platform Empowered by Membrane-Bound IL-15 Under RheoSwitch Therapeutic System® Control
Two CAR Targets Selected Enable Range of Potential Therapeutic Candidates for Both Solid and Liquid Tumors
View HTML
Toggle Summary ZIOPHARM Announces Successful End-of-Phase 2 Meeting with FDA for Ad-RTS-hIL-12 Gene Therapy in Recurrent Glioblastoma
BOSTON, March 27, 2017 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on new immunotherapies, today announced the receipt of positive guidance from an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) for its lead gene therapy
View HTML
Toggle Summary ZIOPHARM Appoints Amy Trevvett Vice President of Investor Relations and Corporate Communications
Company to Host Quarterly Conference Calls
View HTML
Toggle Summary ZIOPHARM Reports Fourth-Quarter 2016 Financial Results and Provides Update on Recent Activities
- Company to Webcast Corporate Update Thursday, February 23, at the 2017 RBC Global Healthcare Conference - BOSTON, Feb. 16, 2017 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on new immunotherapies, today announced financial results for the fourth
View HTML
Toggle Summary ZIOPHARM Utilizing Non-Viral Sleeping Beauty Platform to Rapidly Produce CAR-Expressing T cells Advancing "Point-of-Care" Approach
— First Patient Treated with Non-viral Sleeping Beauty Modified CAR-T Cells Produced in 2 Weeks — Anticipate Phase 1 Clinical Trial Launch in 2017 with Administration of Sleeping Beauty CAR-T Cells Produced within 2 Days — Shortened Process Delivers Genetically Modified T cells with Superior
View HTML